Litcius/Paper detail

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Paul W. Manley, Louise Barys, Sandra W. Cowan‐Jacob

2020Leukemia Research141 citationsDOI

Topics & Concepts

Myeloid leukemiaTyrosine kinaseABLProtein kinase domainKinaseCancer researchK562 cellsPharmacologyChemistryLeukemiaBiologyMutantCell biologyBiochemistrySignal transductionImmunologyGeneChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase | Litcius